# Medicenna Therapeutics Corp. (MDNA)

Source: https://www.quantisnow.com/company/MDNA
Generated: 2026-11-14T01:13:03.269Z

- Ticker: MDNA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- Website: medicenna.com

## About

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA55, which has completed Phase 2b clinical trial to treat rGBM; MDNA109, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease (GvHD); MDNA413, a dual IL-4/IL-13 antagonist to treat solid tumors; and MDNA132, an IL-13 Superkine to chimeric antigen receptor T (CAR-T) platform. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, or naked IL-2, IL-4, and IL-13 Superkines. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

## Latest MDNA news and filings

- 2024-02-14 12:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by Medicenna Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-medicenna-therapeutics-corp-5259367)
- 2024-02-13 15:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by Medicenna Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-medicenna-therapeutics-corp-5253261)
- 2024-02-07 23:55 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Medicenna Therapeutics Corp. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-medicenna-therapeutics-corp-amendment-5238769)
- 2024-01-24 21:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Medicenna Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-medicenna-therapeutics-corp-5204708)
- 2024-01-13 00:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by Medicenna Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-medicenna-therapeutics-corp-5186951)
- 2024-01-09 15:33 UTC [SEC Form 6-K] [SEC Form 6-K filed by Medicenna Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-medicenna-therapeutics-corp-5178517)
- 2024-01-05 14:06 UTC [SEC Form 6-K] [SEC Form 6-K filed by Medicenna Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-medicenna-therapeutics-corp-5172298)
- 2023-12-22 19:13 UTC [SEC Form 6-K] [SEC Form 6-K filed by Medicenna Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-medicenna-therapeutics-corp-5153052)
- 2023-12-22 00:31 UTC [SEC Form 6-K] [SEC Form 6-K filed by Medicenna Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-medicenna-therapeutics-corp-5152094)
- 2023-11-21 15:39 UTC [SEC Form 6-K] [SEC Form 6-K filed by Medicenna Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-medicenna-therapeutics-corp-5098106)
- 2023-11-20 13:49 UTC [SEC Form 25-NSE filed by Medicenna Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-medicenna-therapeutics-corp-5095045)
- 2023-11-09 14:15 UTC [Market Chatter] [Medicenna To Present 4 Year Follow-Up Phase 2b Bizaxofusp Survival Data In Recurrent Glioblastoma At The Society For Neuro-Oncology 2023 Annual Meeting](https://www.quantisnow.com/insight/medicenna-to-present-4-year-follow-up-phase-2b-bizaxofusp-survival-5073448)
- 2023-11-09 13:56 UTC [Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting](https://www.quantisnow.com/insight/medicenna-to-present-4-year-follow-up-phase-2b-bizaxofusp-survival-5073282)
- 2023-11-08 15:29 UTC [SEC Form 6-K] [SEC Form 6-K filed by Medicenna Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-medicenna-therapeutics-corp-5069222)
- 2023-11-06 12:00 UTC [Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)](https://www.quantisnow.com/insight/medicenna-announces-promising-single-agent-response-and-durability-of-mdna11-in-5060455)
- 2023-11-03 16:13 UTC [Market Chatter] [Medicenna Presents Preclinical Data On MDNA113, Its Targeted Metalloprotease Activated SuperKine At The 38th Annual Meeting Of The Society For Immunotherapy Of Cancer](https://www.quantisnow.com/insight/medicenna-presents-preclinical-data-on-mdna113-its-targeted-metalloprotease-activated-5058228)
- 2023-11-03 16:00 UTC [Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)](https://www.quantisnow.com/insight/medicenna-presents-preclinical-data-on-mdna113-its-targeted-metalloprotease-activated-5058125)
- 2023-10-30 12:44 UTC [Market Insight] [Why Biophytis Shares Are Trading Higher By Over 12%: Here Are 20 Stocks Moving Premarket](https://www.quantisnow.com/insight/why-biophytis-shares-are-trading-higher-by-over-12-here-5043121)
- 2023-10-27 17:17 UTC [Market Insight] [Why Barnes Group Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Friday's Mid-Day Session](https://www.quantisnow.com/insight/why-barnes-group-shares-are-trading-lower-by-around-28-5042044)
- 2023-10-27 15:12 UTC [Market Chatter] [Medicenna Therapeutics shares are trading lower after the company announced it will be delisted from the Nasdaq and is cutting back its management team.](https://www.quantisnow.com/insight/medicenna-therapeutics-shares-are-trading-lower-after-the-company-announced-5041877)
- 2023-10-27 13:43 UTC [Market Insight] [Nasdaq Jumps 100 Points; Amazon Posts Upbeat Earnings](https://www.quantisnow.com/insight/nasdaq-jumps-100-points-amazon-posts-upbeat-earnings-5041729)
- 2023-10-27 12:19 UTC [Market Chatter] [Medicenna Announces Nasdaq Delisting And Cutback Of Management Team](https://www.quantisnow.com/insight/medicenna-announces-nasdaq-delisting-and-cutback-of-management-team-5041582)
- 2023-10-27 12:00 UTC [Market Chatter] [Medicenna Therapeutics Gets Staff Delisting Determination From the Listing Qualifications Department Nasdaq On Failure To comply With The $1.00 Per Share Minimum Bid Price Requirement](https://www.quantisnow.com/insight/medicenna-therapeutics-gets-staff-delisting-determination-from-the-listing-qualifications-5041552)
- 2023-10-27 11:55 UTC [Medicenna Announces Nasdaq Delisting and Cutback of Management Team](https://www.quantisnow.com/insight/medicenna-announces-nasdaq-delisting-and-cutback-of-management-team-5041517)
- 2023-10-25 19:56 UTC [Market Chatter] [Reported Earlier, Medicenna Therapeutics Doses First Patient In Phase 2 Monotherapy Dose Expansion Portion Of The ABILITY Study Evaluating MDNA11 In Select Types Of Solid Tumors](https://www.quantisnow.com/insight/reported-earlier-medicenna-therapeutics-doses-first-patient-in-phase-2-5037676)
- 2023-10-25 19:51 UTC [SEC Form 6-K] [SEC Form 6-K filed by Medicenna Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-medicenna-therapeutics-corp-5037669)
- 2023-10-25 11:00 UTC [Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors](https://www.quantisnow.com/insight/medicenna-therapeutics-doses-first-patient-in-phase-2-monotherapy-dose-5036361)
- 2023-10-24 11:18 UTC [SEC Form 6-K] [SEC Form 6-K filed by Medicenna Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-medicenna-therapeutics-corp-5033948)
- 2023-10-24 11:15 UTC [Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer's (SITC)](https://www.quantisnow.com/insight/medicenna-announces-presentations-at-the-38th-annual-meeting-of-the-5033938)
- 2023-10-10 12:57 UTC [SEC Form 6-K] [SEC Form 6-K filed by Medicenna Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-medicenna-therapeutics-corp-5011874)
- 2023-10-10 11:07 UTC [Leadership Update] [Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer](https://www.quantisnow.com/insight/medicenna-therapeutics-appoints-humphrey-gardner-md-as-chief-medical-officer-5011391)
- 2023-10-03 21:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Medicenna Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-medicenna-therapeutics-corp-5001882)
- 2023-10-03 11:00 UTC [Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy](https://www.quantisnow.com/insight/medicenna-presents-preclinical-mdna223-biskit-data-at-the-aacr-special-4998884)
- 2023-09-29 18:09 UTC [Market Insight] [Stocks That Hit 52-Week Lows On Friday](https://www.quantisnow.com/insight/stocks-that-hit-52-week-lows-on-friday-4994785)
- 2023-09-28 21:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Medicenna Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-medicenna-therapeutics-corp-4993377)
- 2023-09-28 21:00 UTC [Leadership Update] [Medicenna Announces Results of Annual and Special Meeting of Shareholders](https://www.quantisnow.com/insight/medicenna-announces-results-of-annual-and-special-meeting-of-shareholders-4993361)
- 2023-09-28 14:59 UTC [SEC Form 6-K] [SEC Form 6-K filed by Medicenna Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-medicenna-therapeutics-corp-4992484)
- 2023-09-28 11:00 UTC [Conference Announcement] [Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy](https://www.quantisnow.com/insight/medicenna-to-present-at-the-aacr-special-conference-cancer-research-4991612)
- 2023-09-06 11:13 UTC [SEC Form 6-K] [SEC Form 6-K filed by Medicenna Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-medicenna-therapeutics-corp-4954660)
- 2023-09-06 11:00 UTC [Conference Announcement] [Medicenna to Participate at The H.C. Wainwright 25th Annual Global Investment Conference](https://www.quantisnow.com/insight/medicenna-to-participate-at-the-hc-wainwright-25th-annual-global-4954575)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/MDNA
- Earnings history: https://www.quantisnow.com/earnings/MDNA
- Dividend history: https://www.quantisnow.com/dividends/MDNA
- Insider transactions: https://www.quantisnow.com/insiders/MDNA
- Options chain: https://www.quantisnow.com/options/MDNA
- SEC 8-K filings only: https://www.quantisnow.com/company/MDNA/8-k
- RSS and alerts for MDNA: https://www.quantisnow.com/docs/rss-feeds.md